

U.S. Patent Application No. 10/628,322
Amendment dated November 19, 2004
Reply to Office Action of August 23, 2004

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (currently amended): A method of treating a malignant tumor in a mammal comprising administering orally to said mammal in need of such treatment an effective amount of a water-insoluble camptothecin compound with a closed-lactone ring at a dose lower than 1.5 mg/Kg/day,

wherein said compound is selected from the group consisting of 20(S)-camptothecin, 9-nitro-20(S)-camptothecin, ~~9-amino-20(s)-camptothecin, dimethylaminomethyl-10-hydroxy-20(S)-camptothecin-(topotecan),~~ 7-ethyl-10-carboxyloxy-camptothecin (camptothecin-11), 7-ethyl-10-hydroxy-20(S)-camptothecin, ~~10,11-methylenedioxy-20(S)-camptothecin,~~ 9-chloro-20(S)-camptothecin, 9-bromo-20(S)-camptothecin, 9-hydroxy-20(S)-camptothecin, 11-hydroxy-20(S)-camptothecin, 10-hydroxy-20(S)-camptothecin, and or mixtures thereof.

Claim 2. (canceled)

Claim 3. (canceled)

Claim 4. (previously presented): The method of claim 1, wherein said camptothecin compound is administered to the mammal at a dose of from about 0.75 to about 1.5 mg/Kg/day.

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin.

Claim 8. (canceled)

Claim 9. (previously presented): The method of claim 1, wherein said camptothecin

U.S. Patent Application No. 10/628,322
Amendment dated November 19, 2004
Reply to Office Action of August 23, 2004

compound is 9-nitro-20(S)-camptothecin and said malignant tumor is breast cancer.

Claim 10. (previously presented): The method of claim 1, wherein the malignant tumor is breast cancer, colon cancer, lung cancer, stomach cancer, ovarian cancer, pancreas cancer, prostate cancer, osteosarcoma, melanoma, or bladder cancer.

Claim 11. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is colon cancer.

Claim 12. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is lung cancer.

Claim 13. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is pancreatic cancer.

Claim 14. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is malignant melanoma.

Claim 15. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is stomach cancer.

Claim 16. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is ovarian cancer.

Claim 17. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor prostate cancer.

Claim 18. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is osteosarcoma.

Claim 19. (previously presented): The method of claim 1, wherein said camptothecin compound is 9-nitro-20(S)-camptothecin and said malignant tumor is bladder cancer.